Enterprise Value
-68.34M
Cash
125.9M
Avg Qtr Burn
-17.48M
Short % of Float
8.48%
Insider Ownership
6.57%
Institutional Own.
61.44%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BDC-1001 +/- pertuzumab Details HER2-expressing cancers | Phase 2 Data readout | |
BDC-3042 Details Solid tumor/s, Cancer | Phase 1 Initiation |